Aegis Therapeutics has received US Patent No. 7,998,927 for stabilized formulations of GLP-1 peptide analogs that can be delivered by a variety of different routes, including intranasal. All currently available GLP-1 formulations, which can control blood sugar and affect weight, such as Lilly-Amylin’s Byetta and Novo Nordisk’s Victoza require once- or twice-daily injection.
According to Aegis, its Intravail/ProTek formulations of these drugs have shown very good nasal bioavailability. Intravail is a series of transmucosal absorption enhancers, and the ProTek technology involves protein and peptide stabilization excipients. Aegis is looking for partners for its intranasal GLP-1 analog technology.
Read the Aegis press release.
